[Antidementia drugs--response or non-response?].

Der Internist
H Förstl

Abstract

Due to the heterogeneous course of illness in individual cases, efficacy or "treatment-response" can not be measured in single patients; therefore a clinical distinction between response and non-response is not meaningful. Constructs which are valid for research projects become misnomers in clinical practice. To date there are two groups of antidementia drugs, memantine--an NMDA-receptor modulator licensed for the moderate to severe stages--and the cholinesterase inhibitors donepezil, galantamine, and rivastigmine, licensed for mild to moderate stages of Alzheimer's disease. These substances exert a moderate symptomatic effect on cognition and activities of daily living or clinical global impression, which corresponds to a parallel shift of the natural course of dementia. A low number of contraindications and few serious adverse events are the advantages of memantine. The extensive evidence for their efficacy and safety are the advantages of cholinesterase inhibitors. Symptoms of "cholinopathy" (a severe lack of acetylcholine) predict a favorable treatment response to cholinesterase inhibitors in groups of demented patients with attention deficit disorders, fluctuating course of illness, visual hallucinations, and superimposed ...Continue Reading

References

Sep 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·H FörstlP Lantos
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Pierre N TariotUNKNOWN Memantine Study Group
Mar 3, 2004·The American Journal of Psychiatry·Jeffrey L CummingsWeiying Yuan
Dec 14, 2004·The New England Journal of Medicine·Stanley FahnUNKNOWN Parkinson Study Group
Dec 14, 2004·The New England Journal of Medicine·Murat EmreRoger Lane
Jun 21, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·B RavinaT Simuni
Jun 30, 2006·International Journal of Clinical Practice·C BallardS Tekin
Jul 13, 2006·Neurology·Jeffrey L CummingsUNKNOWN Memantine MEM-MD-02 Study Group
Jul 22, 2006·Emergency Medicine Journal : EMJ·T SuleymanS Ozlem
Oct 13, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·Roberto MonasteroRosolino Camarda
Nov 17, 2006·Pharmacoepidemiology and Drug Safety·S V FrankfortB A Schmand
May 15, 2007·Dementia and Geriatric Cognitive Disorders·Daniel SaumierHoward Chertkow
Jul 12, 2007·Dementia and Geriatric Cognitive Disorders·Pasquale CalabreseHans Forstl
Aug 1, 2007·Neurology·A P AuchusUNKNOWN GAL-INT-26 Study Group
Aug 19, 2007·Dementia and Geriatric Cognitive Disorders·M Degerman GunnarssonL Lannfelt
Aug 30, 2007·Behavioural Neurology·Rosolino CamardaMassimo Gangitano
Oct 5, 2007·The New England Journal of Medicine·Robert J HowardUNKNOWN CALM-AD Trial Group
Feb 22, 2008·Deutsche medizinische Wochenschrift·H FörstlP Schönknecht

❮ Previous
Next ❯

Citations

Jul 1, 2009·Der Nervenarzt·H Förstl
May 16, 2008·Der Internist·M Gogol, H Förstl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.